Business context and reporting period
The supplied filing is Isoray, Inc.’s unaudited Form 10-Q for the quarter and six months ended December 31, 2021 (fiscal Q2 2022), filed February 9, 2022. This does not match the request metadata identifying Perspective Therapeutics, Inc.; verify the issuer before relying on this summary. Isoray manufactures and sells Cesium-131 brachytherapy seeds and related products and services.
Financial results and liquidity
Amounts below are in millions of dollars unless noted; income and cash-flow comparisons are to the prior-year periods.
| Metric | Three months ended Dec. 31 | Six months ended Dec. 31 |
|---|---|---|
| Net sales | $2.816 vs. $2.359; +19% | $5.380 vs. $4.743; +13% |
| Gross profit / margin | $1.220 / 43% vs. $1.167 / 49% | $2.249 / 42% vs. $2.413 / 51% |
| Operating expenses | $2.855 vs. $2.040 | $6.158 vs. $4.000 |
| Operating loss | $(1.635) vs. $(0.873) | $(3.909) vs. $(1.587) |
| Net loss | $(1.604) vs. $(0.868) | $(3.847) vs. $(1.581) |
| Loss per share | $(0.01) vs. $(0.01) | $(0.03) vs. $(0.02) |
- Six-month operating cash use was $3.397 million, versus $1.098 million; investing cash use was $0.135 million, versus $0.173 million. Financing provided $0.056 million, compared with $8.465 million in the prior year, which included an equity offering.
- At December 31, cash and cash equivalents were $60.354 million; working capital was $61.759 million and the current ratio was 34.47. Total liabilities were $2.861 million, primarily current operating obligations, lease liabilities and an asset retirement obligation. The balance sheet reports no borrowings.
- Management said current cash was expected to cover projected operating cash needs for the next 12 months. This is a forecast, not a guarantee.
Material changes versus the prior comparable period
- Revenue grew, led by other applications and services: other sales increased 46% for the quarter and 32% for six months; prostate sales rose 13% and 9%, respectively.
- Cost of sales rose 34% in both comparisons. Gross margin declined to 43% for the quarter and 42% for six months, as higher isotope, materials and labor costs, excess unused isotope, and supply preparation for a second reactor weighed on results.
- Operating expenses increased 40% for the quarter and 54% for six months, including higher R&D, sales and marketing, and general and administrative costs. Six-month share-based compensation rose to $0.776 million from $0.166 million.
- Cash declined from $63.828 million at June 30, 2021 to $60.354 million at December 31, 2021. The filing’s cash-flow presentation contains a small inconsistency: it reports ending cash, cash equivalents and restricted cash of $60.534 million in one line and $60.536 million in the reconciliation.
Outlook, commentary and risks
- Management targeted 25% fiscal 2022 revenue growth but reported missing that target in the first six months; it gave no assurance the target would be achieved. It estimated cash-flow break-even in three to four years only if growth assumptions are met and no extraordinary expenses arise.
- COVID-19 variants, procedure cancellations or delays, and hospital nurse staffing shortages constrained treatment volumes. Management also cited physician vacations and forecast misses; it planned to manage expenses and adjust isotope orders as permitted.
- Cesium-131 supply depends on Russian suppliers and reactor availability. The company began using a second reactor arrangement through Medikor; the filing notes uncertainty about the supplier, reactor use and timing of available supply.
- Three customers represented approximately 45% of six-month revenue; one customer group accounted for approximately 25%. GT Medical Technologies accounted for 13% of quarterly and 14% of six-month sales, including minimum-order fees.
- CMS finalized continued fee-for-service reimbursement for brachytherapy and its sources, excluding them from the Radiation Oncology Alternative Payment Model; the model’s start was delayed to January 1, 2023. Future reimbursement changes remain a risk.
- Research and development included studies of Cesium-131 in additional cancers and evaluation of an MRI marker product; a full market release was anticipated later in fiscal 2022 but was not assured. The new production facility remained on hold.
- Management said future capital needs could be funded through equity, collaborations, debt or other sources; additional equity financing could dilute existing holders. The company reported no material change in risk factors beyond the customer-concentration disclosure and reimbursement update.
Important facts for investors to verify
- Confirm that this Isoray filing—not a Perspective Therapeutics filing—is the intended document.
- Review the source filing and XBRL for the ending cash/restricted-cash discrepancy and reported operating cash burn.
- Assess whether revenue growth, the missed 25% target and management’s cash runway assumptions are supported by subsequent results.
- Monitor customer concentration, Russian isotope supply and second-reactor execution, and any reimbursement or dilution developments.